Use of Non-ablative Vaginal Erbium YAG Laser for the Treatment of Prolapse (VELPOP)
Primary Purpose
Prolapse
Status
Active
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Non-ablative vaginal Erbium YAG laser treatment
Pelvic floor exercises (PFE)
Sponsored by

About this trial
This is an interventional treatment trial for Prolapse focused on measuring laser, pelvic floor treatment
Eligibility Criteria
Inclusion Criteria:
- The presence of POP symptoms
- Diagnosis of cystocele or rectocele of grade II to IV according to the POP-Q system, leading the prolapse (i.e. C ≤ Ba/Bp)
- Voluntary informed consent
Exclusion Criteria:
- Symptoms or anatomical evidence for intussusception / rectal prolapse
- Leading descent of the middle compartment (C > Ba/Bp)
- Grade IV prolapse
- Previous POP surgery
- Pregnancy or <12 months postpartum
- Vaginal bleeding, injuries or infection in the treated area
Sites / Locations
- UZ Leuven
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Laser
PFE
Arm Description
Outcomes
Primary Outcome Measures
Primary outcome is the subjective improvement of POP symptoms, assessed by the Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6).
Participants have to answer 6 questions concerning POP symptoms with a response scale from 0 to 4 (not present (=0), not at all (=1), somewhat (=2), moderately (=3), quite a bit (=4)). The score (range 0 to 100) is then obtained by multiplying the mean value of all of the answered items by 25. Missing items are dealt with by using the mean from answered items only. Higher scores indicate more distress. This questionnaire is available and validated in English, Dutch and French. Success is defined as a reduction in scores of at least 25% compared with baseline.
Secondary Outcome Measures
Assessment of the anatomical success rate by means of the POP-Q system
Anatomical success is defined as POP-Q = grade 0 (no prolapse) or grade I (leading edge < -1cm)
Assessment of the rate of patient satisfaction by means of the Patient Global Impression of Improvement (PGI)
a 5-point Likert scale (1=much worse, 2=worse, 3=same, 4=better, 5=much better)
Assessment of the degree of discomfort of the treatment procedure by the patient
VAS-score (Visual Analogue Scale: 0-10cm, continuous scale); the higher the score, the higher the discomfort
Assessment of the longevity of the effect of laser therapy
Measured by the need for repeating the same, or initiating an alternative therapy
Assessment of sexual function, by means of the Pelvic Organ prolapse/Urinary Incontinence Sexual Questionnaire IUGA revised (PISQ-IR)
The PISQ-IR is a questionnaire with twenty questions. Q1 is a question to divide the patients based on sexual activity. Not sexually active (NSA) women are referred to Q2-Q6. Sexually active (SA) women are asked to fill out Q7-Q20. The questionnaire for NSA women consists of five questions or 12 items. A higher score refers to a higher impact of PFD on sexual functioning. The questionnaire for SA women consists of 14 questions wherein women with a partner have to fill out all 14, being 22 items. Women without partner can skip questions 13 and 14, filling out 19 items. A lower score refers to a lower impact of PFD on sexual functioning. This questionnaire is available and validated in English, Dutch and French.
Assessment of urinary symptoms by means of the Urogenital Distress Inventory (UDI-6)
The final UDI-6 score is calculated by adding all scores as explained in the above, and dividing the result to 6 to obtain a mean value which is in turn multiplied by 25 to obtain the scale score. The score varies from 0 to 100. The basic interpretation of the score is that the higher the score, the higher the disability. This questionnaire is available and validated in English, Dutch and French.
Full Information
NCT ID
NCT04523298
First Posted
August 11, 2020
Last Updated
May 22, 2023
Sponsor
Universitaire Ziekenhuizen KU Leuven
1. Study Identification
Unique Protocol Identification Number
NCT04523298
Brief Title
Use of Non-ablative Vaginal Erbium YAG Laser for the Treatment of Prolapse
Acronym
VELPOP
Official Title
Use of Non-ablative Vaginal Erbium YAG Laser for the Treatment of Prolapse: a Randomized Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 8, 2020 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a single center, investigator initiated study, sponsored by the UZ Leuven, Leuven, Belgium; comparing laser treatment to pelvic floor exercises (PFE).
Women with symptomatic prolapse (grade II-IV) who seek for a conservative treatment, with no history of previous POP-surgery will be randomised to either the laser-arm or the PFE-arm.
There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.
The primary objective is to evaluate the effects of VEL treatment for reduction of prolapse symptoms and as a secondary outcome objective measurements. These endpoints are in line with the recommendations by Durnea et al., as being the most relevant and patient centered outcomes.
The second goals are to register adverse events and to determine for how long the effects of laser are sustained, with a maximum of two years. To do so, the investigators will measure long term satisfaction with, and the longevity of the effect (measured by the need for repeat or alternative therapy) of laser therapy.
Duration of follow-up per patient: max 27 months
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prolapse
Keywords
laser, pelvic floor treatment
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Laser
Arm Type
Experimental
Arm Title
PFE
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Non-ablative vaginal Erbium YAG laser treatment
Intervention Description
There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.
Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).
Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area.
Intervention Type
Other
Intervention Name(s)
Pelvic floor exercises (PFE)
Intervention Description
Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
Primary Outcome Measure Information:
Title
Primary outcome is the subjective improvement of POP symptoms, assessed by the Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6).
Description
Participants have to answer 6 questions concerning POP symptoms with a response scale from 0 to 4 (not present (=0), not at all (=1), somewhat (=2), moderately (=3), quite a bit (=4)). The score (range 0 to 100) is then obtained by multiplying the mean value of all of the answered items by 25. Missing items are dealt with by using the mean from answered items only. Higher scores indicate more distress. This questionnaire is available and validated in English, Dutch and French. Success is defined as a reduction in scores of at least 25% compared with baseline.
Time Frame
6 months after last treatment
Secondary Outcome Measure Information:
Title
Assessment of the anatomical success rate by means of the POP-Q system
Description
Anatomical success is defined as POP-Q = grade 0 (no prolapse) or grade I (leading edge < -1cm)
Time Frame
At every visit (ie. week 4, 8 and 12, optional: 16, 20 and 24 weeks), 6, 12 and 24 months after end of treatment
Title
Assessment of the rate of patient satisfaction by means of the Patient Global Impression of Improvement (PGI)
Description
a 5-point Likert scale (1=much worse, 2=worse, 3=same, 4=better, 5=much better)
Time Frame
At every visit (ie. week 4, 8 and 12, optional: 16, 20 and 24 weeks), 6, 12 and 24 months after end of treatment
Title
Assessment of the degree of discomfort of the treatment procedure by the patient
Description
VAS-score (Visual Analogue Scale: 0-10cm, continuous scale); the higher the score, the higher the discomfort
Time Frame
At every visit (ie. week 4, 8 and 12, optional: 16, 20 and 24 weeks), 6, 12 and 24 months after end of treatment
Title
Assessment of the longevity of the effect of laser therapy
Description
Measured by the need for repeating the same, or initiating an alternative therapy
Time Frame
At every visit (ie. week 4, 8 and 12), end of treatment (ie. 4 months after randomisation), 6, 12 and 24 months after end of treatment
Title
Assessment of sexual function, by means of the Pelvic Organ prolapse/Urinary Incontinence Sexual Questionnaire IUGA revised (PISQ-IR)
Description
The PISQ-IR is a questionnaire with twenty questions. Q1 is a question to divide the patients based on sexual activity. Not sexually active (NSA) women are referred to Q2-Q6. Sexually active (SA) women are asked to fill out Q7-Q20. The questionnaire for NSA women consists of five questions or 12 items. A higher score refers to a higher impact of PFD on sexual functioning. The questionnaire for SA women consists of 14 questions wherein women with a partner have to fill out all 14, being 22 items. Women without partner can skip questions 13 and 14, filling out 19 items. A lower score refers to a lower impact of PFD on sexual functioning. This questionnaire is available and validated in English, Dutch and French.
Time Frame
At every visit (ie. week 4, 8 and 12, optional: 16, 20 and 24 weeks), 6, 12 and 24 months after end of treatment
Title
Assessment of urinary symptoms by means of the Urogenital Distress Inventory (UDI-6)
Description
The final UDI-6 score is calculated by adding all scores as explained in the above, and dividing the result to 6 to obtain a mean value which is in turn multiplied by 25 to obtain the scale score. The score varies from 0 to 100. The basic interpretation of the score is that the higher the score, the higher the disability. This questionnaire is available and validated in English, Dutch and French.
Time Frame
At every visit (ie. week 4, 8 and 12, optional: 16, 20 and 24 weeks), 6, 12 and 24 months after end of treatment
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
The presence of POP symptoms
Diagnosis of cystocele or rectocele of grade II to IV according to the POP-Q system, leading the prolapse (i.e. C ≤ Ba/Bp)
Voluntary informed consent
Exclusion Criteria:
Symptoms or anatomical evidence for intussusception / rectal prolapse
Leading descent of the middle compartment (C > Ba/Bp)
Grade IV prolapse
Previous POP surgery
Pregnancy or <12 months postpartum
Vaginal bleeding, injuries or infection in the treated area
Facility Information:
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Use of Non-ablative Vaginal Erbium YAG Laser for the Treatment of Prolapse
We'll reach out to this number within 24 hrs